AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20569270 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (150 IU thrice per week for 3 months)
Number of subjects: 105
Study 20569270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 105
Study 20569270 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (subgroup analysis based on FSHR genotype)
Number of subjects: 105
Study 19016015 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy with simultaneous temozolomide (RT + TMZ)
Number of subjects: 65
Study 19016015 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy alone (RT)
Number of subjects: 65
Study 16784014 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified allergen extract of Dermatophagoides pteronyssinus
Number of subjects: 30
Study 16784014 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic treatment (control group)
Number of subjects: 30
Study 12915642 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin tablets (1.25/250 mg)
Number of subjects: 486
Study 12915642 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg)
Number of subjects: 486
Study 12915642 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (2.5 mg)
Number of subjects: 486
Study 12915642 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin tablets
Number of subjects: 486
Study 10566359 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system for ventilator management
Number of subjects: 200
Study 8750803 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxyvitamin D3 (1 alpha‐OHD3) at a dose of 0.05 microgram/kg per day for 1 year
Number of subjects: 12
Study 2006963 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthing stool (experimental group)
Number of subjects: 294
Study 2006963 — intervention group
Group type: COMPARATOR
Intervention: Conventional semirecumbent position (control group)
Number of subjects: 294
Study 6756537 — intervention group
Group type: EXPERIMENTAL
Intervention: SPTU circular stapling instrument
Number of subjects: 100
Study 6756537 — intervention group
Group type: COMPARATOR
Intervention: Single layer of braided polyester interrupted sutures
Number of subjects: 100
Study 31152038 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.01 mg/day
Number of subjects: 54
Study 31152038 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.005 mg/day
Number of subjects: 54
Study 31152038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31152038 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (both dosages)
Number of subjects: 54
Study 28899338 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope (GL)
Number of subjects: 140
Study 28899338 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MCL)
Number of subjects: 140
Study 26996228 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of fruits and vegetables (≥500 g daily)
Number of subjects: 68
Study 26996228 — intervention group
Group type: EXPERIMENTAL
Intervention: General dietary advice + fruits and vegetables
Number of subjects: 68
Study 26996228 — intervention group
Group type: COMPARATOR
Intervention: General dietary advice (reference group)
Number of subjects: 68
Study 26996228 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of fruits and vegetables
Number of subjects: 68
Study 24706088 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (150 or 100 mg/day according to body weight)
Number of subjects: 126
Study 24706088 — intervention group
Group type: COMPARATOR
Intervention: Control (no antiarrhythmic drugs)
Number of subjects: 126
Study 22997331 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving from a high-poverty to lower-poverty neighborhood
Number of subjects: 9000000
Study 22997331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-standard deviation decline in neighborhood poverty (13 percentage points)
Number of subjects: 9000000
Study 22997331 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9000000
Study 20665492 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 32
Study 20665492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18158803 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic varicocelectomy (LV)
Number of subjects: 100
Study 18158803 — intervention group
Group type: COMPARATOR
Intervention: Open varicocelectomy (OV)
Number of subjects: 100
Study 11127861 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental response to APC
Number of subjects: 1519
Study 11127861 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic resistance to APC in both parents and sibs
Number of subjects: 1519
Study 11127861 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 allele of exon 13 of FV gene
Number of subjects: 1519
Study 9069612 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus MLT (20 mg/day p.o. in the evening)
Number of subjects: 80
Study 9069612 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 80
Study 8250350 — intervention group
Group type: EXPERIMENTAL
Intervention: Wright peak flow meter
Number of subjects: 457
Study 8250350 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐Wright peak flow meter
Number of subjects: 457
Study 8250350 — intervention group
Group type: COMPARATOR
Intervention: Comparison with European and American children
Number of subjects: 457
Study 8250350 — intervention group
Group type: COMPARATOR
Intervention: Comparison with Swedish and British children
Number of subjects: 457
Study 3082163 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 350 mg l/ml (iohexol)
Number of subjects: 53
Study 3082163 — intervention group
Group type: COMPARATOR
Intervention: Hexabrix 320 mg l/ml (ioxaglate)
Number of subjects: 53
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Social pressure for addiction to pornography
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Social pressure for addiction to marijuana
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Social pressure for addiction to alcohol
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Social pressure for addiction to heroin
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to gambling
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to marijuana
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to pornography
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to heroin
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to alcohol
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Upbringing for addiction to marijuana
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Upbringing for addiction to heroin
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Upbringing for addiction to alcohol
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics for addiction to alcohol
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics for addiction to pornography
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics for addiction to marijuana
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics for addiction to gambling
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics for addiction to heroin
Number of subjects: 612
Study 30798775 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful circumstances and character problems
Number of subjects: 612
Study 26593266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebselen
Number of subjects: 0
Study 26593266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24070115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon suppository (1,000 IU) administered daily for 24 weeks
Number of subjects: 28
Study 24070115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24473588 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 20447654 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge with continued rehabilitation at home (ESD)
Number of subjects: 83
Study 20447654 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 83
Study 18628722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 88
Study 18628722 — intervention group
Group type: COMPARATOR
Intervention: Macular grid laser
Number of subjects: 88
Study 18628722 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete posterior vitreous detachment
Number of subjects: 88
Study 15947913 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 mg/ml
Number of subjects: 120
Study 15947913 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 2.5 mg/ml
Number of subjects: 120
Study 15947913 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 10 mg/ml with adrenaline
Number of subjects: 120
Study 12821736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transplantation of embryonic mesencephalic dopamine cells
Number of subjects: 40
Study 12821736 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery (sham craniotomies)
Number of subjects: 40
Study 10655439 — intervention group
Group type: COMPARATOR
Intervention: FAC (5-fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 78
Study 10655439 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC followed by high-dose chemotherapy (cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support)
Number of subjects: 78
Study 10655439 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 78
Study 9289427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment and spasmolytic drugs for patients with threatened abortion
Number of subjects: 130
Study 9289427 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women in the first trimester of gestation
Number of subjects: 130
Study 9289427 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with threatened abortion
Number of subjects: 130
Study 1671631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine plus prednisone (6 g/d sulphasalazine, 30 mg/d prednisone initially, tapered to 10 mg/d after 8 weeks)
Number of subjects: 60
Study 1671631 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine alone (6 g/d, placebo for prednisone)
Number of subjects: 60
Study 1671631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine plus prednisone
Number of subjects: 60
Study 1671631 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine alone
Number of subjects: 60
Study 30690731 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-based probability condition
Number of subjects: 0
Study 30690731 — intervention group
Group type: COMPARATOR
Intervention: Description-based probability condition
Number of subjects: 0
Study 29100262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold drink
Number of subjects: 0
Study 29100262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DM)
Number of subjects: 0
Study 29100262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (cold drink + dexamethasone)
Number of subjects: 0
Study 29100262 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29231518 — intervention group
Group type: EXPERIMENTAL
Intervention: Awn-like needle at Tiantu (CV 22)
Number of subjects: 100
Study 29231518 — intervention group
Group type: COMPARATOR
Intervention: Filiform needle
Number of subjects: 100
Study 24500930 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-fortified rice (n = 25)
Number of subjects: 50
Study 24500930 — intervention group
Group type: COMPARATOR
Intervention: Natural rice (n = 25)
Number of subjects: 50
Study 22322141 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane® only
Number of subjects: 13
Study 22322141 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane® and autologous cell suspension using the ReCell® kit
Number of subjects: 13
Study 22322141 — intervention group
Group type: COMPARATOR
Intervention: Local standard treatment (Intrasite™, Acticoat™, and Duoderm(®) dressings every 2‐3 days) with surgery at 10 days
Number of subjects: 13
Study 18279821 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally
Number of subjects: 488
Study 16170293 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture sessions plus acupressure
Number of subjects: 88
Study 16170293 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide infusion supplemented by vitamin B12 complex
Number of subjects: 88
Study 12826840 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 at a dose of up to 50 ml/kg
Number of subjects: 120
Study 12826840 — intervention group
Group type: COMPARATOR
Intervention: 6% HES 200/0.5 at a dose of up to 33 ml/kg
Number of subjects: 120
Study 10916176 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical equipoise
Number of subjects: 0
Study 10916176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding-scale equipoise
Number of subjects: 0
Study 8938603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological agents designed to augment functional recovery of the injured spinal cord
Number of subjects: 0
Study 8938603 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs evaluated through scientific and regulatory processes
Number of subjects: 0
Study 8938603 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification scheme based on FDA regulations for drug availability
Number of subjects: 0
Study 1510257 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (3 mL)
Number of subjects: 59
Study 1510257 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine 1:200,000 (1 mL, diluted to 3 mL with normal saline)
Number of subjects: 59
Study 1510257 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine 1:200,000 (2 mL, diluted to 3 mL with normal saline)
Number of subjects: 59
Study 1510257 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine 1:200,000 (3 mL, diluted to 3 mL with normal saline)
Number of subjects: 59
Study 1510257 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-15 and EPI-10 groups
Number of subjects: 59
Study 1510257 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-10 group
Number of subjects: 59
Study 1510257 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-15 group
Number of subjects: 59
Study 1510257 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 59
Study 6828830 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (75 Hz, 0.1 ms, voltage 5-10 V, 10 contractions of 10 seconds with 50 seconds rest)
Number of subjects: 16
Study 6828830 — intervention group
Group type: COMPARATOR
Intervention: Isometric training (10 maximal contractions of 10 seconds with 50 seconds rest)
Number of subjects: 16
Study 31066775 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI‐TS services over a 9‐month period
Number of subjects: 110
Study 31066775 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 30015544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) with light glasses for 4 weeks
Number of subjects: 39
Study 30015544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) for 4 weeks
Number of subjects: 39
Study 26787148 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community case management (iCCM) strategy
Number of subjects: 31
Study 26787148 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 31
Study 25149706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 30
Study 22829023 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan alone or in combination with Ramipril
Number of subjects: 31546
Study 19439364 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200-300 mg/day depending on weight)
Number of subjects: 46
Study 19439364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19439364 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 46
Study 19102753 — intervention group
Group type: EXPERIMENTAL
Intervention: GINA guidelines treatment for 2 months
Number of subjects: 50
Study 19102753 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 16184038 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling program encouraging abrupt cessation of breast-feeding at 4 months (group A)
Number of subjects: 653
Study 16184038 — intervention group
Group type: COMPARATOR
Intervention: Counseling program encouraging prolonged breast-feeding for the duration of the woman's own informed choice (group B)
Number of subjects: 653
Study 12167276 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + Lamivudine (3TC)
Number of subjects: 129
Study 12167276 — intervention group
Group type: COMPARATOR
Intervention: Stavudine (d4T) alone
Number of subjects: 129
Study 12167276 — intervention group
Group type: COMPARATOR
Intervention: Stavudine (d4T) + Zidovudine (ZDV)
Number of subjects: 129
Study 12167276 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + Stavudine (d4T)
Number of subjects: 129
Study 10588075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibition (part of the Sorbinil Retinopathy Trial)
Number of subjects: 407
Study 10588075 — intervention group
Group type: COMPARATOR
Intervention: Baseline variables (age and treatment assignment adjusted)
Number of subjects: 407
Study 7496757 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate systemic hypothermia (32 degrees C) for 24-48 hours with slow rewarming
Number of subjects: 500
Study 7496757 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard management at hypothermia
Number of subjects: 500
Study 7496757 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen administered every 8 hours for 1-hour duration for a 2-week period
Number of subjects: 500
Study 7496757 — intervention group
Group type: COMPARATOR
Intervention: Standard management at normothermia
Number of subjects: 500
Study 2170930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous application of trinitrine
Number of subjects: 23
Study 622696 — intervention group
Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC)
Number of subjects: 83
Study 622696 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 83
Study 622696 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 83
Study 31992802 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12, minimum 6.5 × 10^9 CFU)
Number of subjects: 230
Study 31992802 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 230
Study 31831868 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg daily for 4 months
Number of subjects: 30
Study 31831868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d
Number of subjects: 33
Study 28295959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 28295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d (first exposure)
Number of subjects: 33
Study 28295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d (second exposure)
Number of subjects: 33
Study 28295959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d (first and second exposure correlation)
Number of subjects: 33
Study 26695794 — intervention group
Group type: EXPERIMENTAL
Intervention: Different drug therapies for type A (acute sensorineural hearing loss in low tone frequencies)
Number of subjects: 1024
Study 26695794 — intervention group
Group type: EXPERIMENTAL
Intervention: Different drug therapies for type C (acute sensorineural hearing loss in all frequencies)
Number of subjects: 1024
Study 26695794 — intervention group
Group type: EXPERIMENTAL
Intervention: Different drug therapies for type B (acute sensorineural hearing loss in high tone frequencies)
Number of subjects: 1024
Study 26695794 — intervention group
Group type: EXPERIMENTAL
Intervention: Different drug therapies for type D (total deafness)
Number of subjects: 1024
Study 26695794 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of curative rates among different types
Number of subjects: 1024
Study 26695794 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of four different treatment groups
Number of subjects: 1024
Study 23648620 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training
Number of subjects: 60
Study 23648620 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration training)
Number of subjects: 60
Study 21266519 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year progression-free survival (PFS) / event-free survival (EFS) for aggressive NHL
Number of subjects: 127
Study 21266519 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete response for indolent NHL
Number of subjects: 127
Study 19846022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 0
Study 19846022 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 0